

## Erratum to: PET imaging with a [<sup>68</sup>Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

A. Afshar-Oromieh · A. Malcher · M. Eder · M. Eisenhut ·  
H. G. Linhart · B. A. Hadaschik · T. Holland-Letz ·  
F. L. Giesel · C. Kratochwil · S. Haufe · U. Haberkorn ·  
C. M. Zechmann

Published online: 2 March 2013  
© Springer-Verlag Berlin Heidelberg 2013

### Erratum to: Eur J Nucl Med Mol Imaging DOI 10.1007/s00259-012-2298-2

Four of the six patients who were further investigated by biopsy were unfortunately misnumbered. The correct

numbers are: 10, 16, 19, 21–23. All PSMA-positive lesions which were histologically investigated were confirmed as prostate cancer and metastases.

Patient no. 21 with an initial high Gleason Score (Table 1) had two lymph node metastases and one soft tissue

---

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00259-012-2298-2>.

---

A. Afshar-Oromieh (✉) · A. Malcher · F. L. Giesel ·  
C. Kratochwil · S. Haufe · U. Haberkorn · C. M. Zechmann  
Department of Nuclear Medicine, University Hospital of  
Heidelberg, Im Neuenheimer Feld 400,  
69120 Heidelberg, Germany  
e-mail: a.afshar@gmx.de

A. Malcher  
e-mail: anna.malcher@gmx.de

F. L. Giesel  
e-mail: f.giesel@dkfz.de

C. Kratochwil  
e-mail: clemens.kratochwil@t-online.de

S. Haufe  
e-mail: sabine.haufe@med.uni-heidelberg.de

U. Haberkorn  
e-mail: uwe.haberkorn@med.uni-heidelberg.de

C. M. Zechmann  
e-mail: christian.zechmann@med.uni-heidelberg.de

M. Eder · M. Eisenhut  
Department of Radiopharmaceutical Chemistry, German Cancer  
Research Center, Im Neuenheimer Feld 280,  
Heidelberg, Germany

M. Eder  
e-mail: m.eder@dkfz.de

M. Eisenhut  
e-mail: m.eisenhut@dkfz.de

H. G. Linhart  
National Center for Tumor Diseases (NCT)/DKFZ,  
Im Neuenheimer Feld 581,  
69120 Heidelberg, Germany  
e-mail: heinz.linhart@med.uni-heidelberg.de

B. A. Hadaschik  
Department of Urology, University Hospital of Heidelberg,  
Im Neuenheimer Feld 110,  
Heidelberg, Germany  
e-mail: boris.hadaschik@med.uni-heidelberg.de

T. Holland-Letz  
Department of Biostatistics, German Cancer Research Center,  
Im Neuenheimer Feld 280,  
Heidelberg, Germany  
e-mail: t.holland-letz@dkfz.de

U. Haberkorn  
Clinical Cooperation Unit Nuclear Medicine, German Cancer  
Research Centre, Heidelberg, Germany

metastasis (histologically confirmed). Therefore, amongst the selected 65 representative lesions (Fig. 5), 11 were defined as local relapses (nos. 1, 11, 12, 14, 15, 22, 23, 44, 54, 57, and 58), 24 as bone metastases (nos. 5–9, 18–20, 24, 30–34, 43, 50–53, 59, 61, 62, 64, and 65), 23 as lymph node metastases (nos. 2–4, 10, 16, 17, 21, 25–29, 35, 37, 39,

40, 42, 45–48, 60, and 63) and 7 as soft tissue metastases (nos. 13, 36, 38, 41, 49, 55, and 56).

Neither the results and the message of this study nor the measurements and values of the lesions listed in Fig. 5 are affected by this correction. The authors regret the errors and any inconvenience caused.